Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health care antiseptic update

This article was originally published in The Tan Sheet

Executive Summary

FDA is unable to respond to CTFA/SDA citizen petition asking agency to reopen rulemaking for the tentative final monograph for OTC health care antiseptic drug products to consider more recent scientific information due to "existence of other priorities," agency states in April 16 letter to Cosmetic, Toiletry & Fragrance Association and Soap & Detergent Association. FDA says it will respond when it has reached a decision on the groups' request. CTFA/SDA had filed the petition in 2001 (1"The Tan Sheet" Aug. 13, 2001, p. 4)...

You may also be interested in...



Antimicrobial Data Support CTFA/SDA Performance Criteria - Petition

A comprehensive literature review of topical antimicrobial data "corroborates" the suitability of the product performance criteria advocated by industry, the Cosmetic, Toiletry & Fragrance Association and Soap & Detergent Association maintain in an Aug. 6 joint submission to FDA.

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel